New vaccine development for chronic brain disease

Neuropsychopharmacology

Volumn 35, Issue 1, 2010, Pages 354-

  Barrett, Alan D T ^a   Kayed, Rakez ^a   Jackson, George R ^a   Cunningham, Kathryn A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; COCAINE; METHAMPHETAMINE; MORPHINE; NICOTINE; VACCINE;

ADDICTION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; BEHAVIOR DISORDER; CHRONIC BRAIN DISEASE; DRUG EFFICACY; ENCEPHALITIS; HUMAN; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; CHRONIC DISEASE; HUMANS; IMMUNIZATION; SUBSTANCE-RELATED DISORDERS; VACCINES;

EID: 72049101523     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.147     Document Type: Short Survey

References (5)

1. Chackerian B, Rangel M, Hunter Z, Peabody DS (2006). Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-B without concomitant T cell responses. Vaccine 24: 6321-6331.
2. Gromowski GD, Barrett ADT (2007). Characterization of an antigenic site that contains a dominant, type-specific, neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349-360.
3. Kayed R, Jackson GR (2009). Prefilament tau species as potential targets for immunotherapy for Alzheimer's disease and related disorders. Curr Opin Immunol 21: 1-5.
4. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR (2008). Substance abuse vaccines. Ann N Y Acad Sci 1141: 257-269.
5. Reed SG, Bertholet S, Coler RN, Friede M (2009). New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.